ImageneBio Inc., formerly known as Ikena Oncology, Inc., has announced a change in its independent registered public accounting firm. On August 2, 2025, the company's Audit Committee dismissed Ernst & Young LLP (EY) from this role, effective immediately. EY had audited the company's financial statements for the years ending December 31, 2024, and 2023, without any adverse opinions or disclaimers. There were no disagreements or reportable events between the company and EY during this period. Subsequently, PricewaterhouseCoopers LLP (PwC) has been appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. PwC previously served as the auditor for Inmagene Biopharmaceuticals before its merger with ImageneBio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.